Equity Profile
Pre-Earnings Brief
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health.
Revenue Growth
Revenue growth reflects the company's ability to expand its market presence and commercial success.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
88%
Avg EPS Surprise
+52.29%
Avg Stock Reaction
+1.02%
In Q1 2026, Ionis reported an EPS of -$0.56, outperforming estimates by 37.36%. The stock reacted positively, gaining 4.25% the following day.
Management Promises & Guidance
Overall expectations for Ionis are mixed, with a history of beating EPS estimates but uncertainty around revenue figures. Investors will be keenly watching for updates on the drug pipeline.
Bull Case
If Ionis continues its trend of beating EPS estimates, it could signal strong operational efficiency and market confidence, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a significant drop in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and commercial success.
Pipeline Progress
N/AUpdates on the drug pipeline can indicate future revenue potential and market positioning.
Expectations
The print will turn on these two things.
Q1
What is the current status of Ionis's drug pipeline, particularly any late-stage candidates?
Updates on the pipeline can significantly impact future revenue projections and investor confidence.
Q2
Will the company provide guidance on expected revenue for the upcoming quarters?
Guidance on revenue can help investors gauge the company's growth trajectory and market demand.
Edge
Why consensus could be wrong
The Street may be underestimating the potential impact of Ionis's pipeline developments, which could drive significant revenue growth.
Supporting Evidence
Ionis has a strong track record of beating EPS estimates, suggesting operational strength.
The options market is pricing a larger move than historical averages, indicating heightened expectations.
Insider selling may reflect a strategic repositioning rather than a lack of confidence in the company's future.
Key Risk
If the pipeline updates are more favorable than expected, it could challenge current market skepticism.
Edge
Pre-commit to what would confirm each case.
The market is weighing the potential for growth against the risks associated with pipeline delays and revenue uncertainty.
Bull Confirmed If
A positive update on the drug pipeline, especially for late-stage candidates, could confirm the bull case.
Bear Confirmed If
Failure to provide any meaningful updates or disappointing pipeline news could confirm the bear case.
Pre-Earnings Positioning
Implied Move
±5.44%
Historical Avg
±3.0%
The options market is pricing in a notable move, suggesting that traders anticipate volatility around the earnings report.
Options are pricing ±5.4% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
27.7%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.2M
16,494 sh
4 insiders
Net
$1.2M
Net selling
Most Active Insiders· 5 open-market trades
$381,366.52
Net selling
$418,952.64
Net selling
$368,488.24
Net selling
$73,015.87
Net selling
Recent Transactions
Apr 16, 2026 · @ $74.56
5,619 sh
$418,952.64
Apr 16, 2026 · @ $75.17
4,902 sh
$368,488.24
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Ionis beats expectations and raises guidance, history suggests the stock could rise by around 1.92%, confirming positive momentum.
In-Line / Cautious
If results are in line but management expresses caution, the stock may see muted movement as investors digest the commentary.
Miss
A miss on earnings could lead to a decline, with history suggesting an average drop of 5.29% in such scenarios.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK, Inc.
Apr 15, 2026 · @ $76.19
4,466 sh
$340,264.54
Apr 16, 2026 · @ $75.04
973 sh
$73,015.87
Apr 15, 2026 · @ $76.97
534 sh
$41,101.98